PubMed Health⌕ Search

Biomedical subjects

T Hashizume

Publications and source records attributed to T Hashizume.

310 records · Page 18Linked to original sources

Immunoscintigraphy using 99mTc-labeled anti-CEA monoclonal antibody for patients with colorectal cancer.

Immunoscintigraphy by 99mTc labeled mouse CEA antibody, BW 431/26, was done for 14 patients with colorectal cancer. All patients underwent body scan 6 and 24 hours after administration of 99mTc antibody, 30 mCi/1mg. In 13 out of 14 cases (92.9%) with colorectal cancer, the specific accumulation of 99mTc was shown. The count ratio between the lesion and normal tissue indicating the accumulation of labeled antibody was calculated as 2.6 to 12.8. The hepatic metastasis could be demonstrated as cold spots in one case and as hot spots in the other case. No adverse reaction was noticed in any of patients examined. These results indicate that immunoscintigraphy by 99mTc-CEA antibody detects carcinoma of the colon excellently, and is quite useful clinically. With SPECT, it is possible to localize the site of the lesion more distinctly and to predict the accumulation of the antibody in the tumor as a treatment application.

Adult↗

Temporal changes in neuro-immuno endocrine system with adjuvant radiotherapy for advanced rectal cancer.

The purpose of this study was to evaluate the effect of adjuvant radiotherapy for advanced rectal cancers on the human neuro-immuno-endocrine system. Fifty-seven patients with rectal cancer were investigated. Abdominoperineal resection (APR) was carried out on all of them. The levels of serum IAP in 4-12 weeks after operation were significantly higher in the preoperative radiotherapy group compared with those of non-preoperatively irradiated (p < 0.05). With preoperative radiotherapy, serum IAP levels in patients with postoperative intracavitary cone irradiation returned to normal values within three months of operation; however, those with postoperative external pelvic irradiation continued to be significantly elevated until six months after operation. We conclude that preoperative radiotherapy combined with post-operative external pelvic irradiation is likely to exert unfavorable effects on the human immuno-endocrine system.

Adrenocorticotropic Hormone↗

Temporal changes in ACTH, cortisol and IAP in rats under immunochemotherapy with 5-FU and Krestine.

In this study we investigated temporal changes in both the endocrine system and immunity in rats under immunochemotherapy with 5-FU and Krestine (PSK). This immunochemotherapy was performed on two types of groups, non-cancer-bearing rats and cancer-bearing rats. As hosts, inbred strain WKA/HA 5-week-old male rats and as tumors, transplantable ascitic liver cancer KDH-8 cells were used. Our results indicated that 1) in the non-cancer-bearing rats, 5-FU administration led to an increase in serum cortisol and IAP, however, PSK concurrent administration clearly lowered the levels of cortisol and IAP; 2) in the cancer-bearing rats, the levels of ACTH, cortisol and IAP increased as the cancer progressed, but in the immunothemotherapy administration groups these levels were lower; 3) the immunothemotherapy administration group had greater effects on both tumor growth and liver metastasis.

Adjuvants, Immunologic↗

Vascular endothelial growth factor and its receptor correlate with angiogenesis and survival in pulmonary adenocarcinoma.

The vascular endothelial growth factor (VEGF) and its receptor (Flt) protein expression was immunologically studied individually and in combination with the microvascular density (MVD) determined by the factor 8-related antigen (F8RA) and their prognostic value in 118 patients with a pulmonary adenocarcinoma. The presence of VEGF and Flt was associated with the MVD and prognosis. A reduced expression of both of VEGF and Flt correlated with less tumor angiogenesis and a better prognosis. Our findings suggest that VEGF and Flt expressions play an important role in tumor angiogenesis and that the VEGF and Flt coexpression promotes angiogenesis and metastasis in pulmonary adenocarcinoma.

Adenocarcinoma↗